Recent News

• 10.03.2025 - ALX Oncology to Present Updated Data from Phase 2 ASPEN-06 Trial, Highlighting CD47 Expression as a Predictive Biomarker in HER2+ Gastric Cancer, at 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting
• 10.03.2025 - ALX Oncology to Present Updated Data from Phase 2 ASPEN-06 Trial, Highlighting CD47 Expression as a Predictive Biomarker in HER2+ Gastric Cancer, at 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting
• 09.12.2025 - ALX Oncology Appoints Board Member Barbara Klencke, M.D., as Interim Chief Medical Officer
• 09.12.2025 - ALX Oncology Appoints Board Member Barbara Klencke, M.D., as Interim Chief Medical Officer
• 09.05.2025 - H.C. Wainwright 27th Annual Global Investment Conference
• 09.05.2025 - H.C. Wainwright 27th Annual Global Investment Conference
• 08.29.2025 - ALX Oncology to Participate in Upcoming Investor Conferences in September
• 08.29.2025 - ALX Oncology to Participate in Upcoming Investor Conferences in September
• 08.25.2025 - Daniel J. Curran, M.D.
• 08.25.2025 - Daniel J. Curran, M.D.

Recent Filings

• 09.19.2025 - 4 Statement of changes in beneficial ownership of securities
• 09.18.2025 - 4 Statement of changes in beneficial ownership of securities
• 09.12.2025 - EX-99.1 EX-99.1
• 09.12.2025 - 8-K Current report
• 08.20.2025 - 4 Statement of changes in beneficial ownership of securities
• 08.19.2025 - 4 Statement of changes in beneficial ownership of securities